Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1NET 1Genitourinary 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × PT-100 dipeptide × Gastrointestinal × Clear all
NCT04123574 2022-02-24

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

BioXcel Therapeutics Inc

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00116389 2007-06-08

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Point Therapeutics

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡